Wall Street analysts expect that Mylan (NASDAQ:MYL) will announce $2.83 billion in sales for the current quarter, according to Zacks. Three analysts have provided estimates for Mylan’s earnings, with the lowest sales estimate coming in at $2.78 billion and the highest estimate coming in at $2.90 billion. Mylan posted sales of $2.72 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 4%. The firm is expected to report its next quarterly earnings results on Wednesday, May 9th.
On average, analysts expect that Mylan will report full year sales of $2.83 billion for the current fiscal year, with estimates ranging from $12.39 billion to $12.56 billion. For the next fiscal year, analysts expect that the company will post sales of $13.05 billion per share, with estimates ranging from $12.80 billion to $13.24 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Mylan.
Mylan (NASDAQ:MYL) last issued its quarterly earnings data on Wednesday, February 28th. The company reported $1.43 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.41 by $0.02. Mylan had a net margin of 5.84% and a return on equity of 19.14%. The business had revenue of $3.24 billion during the quarter, compared to analysts’ expectations of $3.29 billion. During the same period last year, the company posted $1.57 EPS. The company’s revenue was down .9% on a year-over-year basis.
Shares of Mylan (NASDAQ:MYL) traded down $0.33 on Friday, hitting $42.02. 3,140,627 shares of the stock were exchanged, compared to its average volume of 5,664,567. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.73 and a current ratio of 1.13. Mylan has a fifty-two week low of $29.39 and a fifty-two week high of $47.82. The stock has a market cap of $21,800.00, a PE ratio of 32.15, a price-to-earnings-growth ratio of 1.36 and a beta of 1.35.
In other Mylan news, CEO Heather M. Bresch sold 75,000 shares of Mylan stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total value of $3,375,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Robert J. Coury sold 150,000 shares of Mylan stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $40.10, for a total transaction of $6,015,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 344,287 shares of company stock worth $14,409,960. 0.69% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the business. Greenlight Capital Inc. boosted its holdings in shares of Mylan by 0.4% in the 3rd quarter. Greenlight Capital Inc. now owns 10,744,307 shares of the company’s stock valued at $337,048,000 after purchasing an additional 42,600 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Mylan by 30.3% during the 4th quarter. Bank of New York Mellon Corp now owns 5,334,789 shares of the company’s stock valued at $225,715,000 after acquiring an additional 1,239,089 shares in the last quarter. Orbimed Advisors LLC lifted its holdings in shares of Mylan by 20.9% during the 3rd quarter. Orbimed Advisors LLC now owns 3,601,100 shares of the company’s stock valued at $112,967,000 after acquiring an additional 621,900 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Mylan by 20.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,553,480 shares of the company’s stock valued at $111,450,000 after acquiring an additional 612,513 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Mylan during the 4th quarter valued at $137,023,000. Institutional investors own 84.82% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3262034/mylan-myl-expected-to-post-quarterly-sales-of-2-83-billion.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.